Tempest Therapeutics Inc
$ 2.95
2.79%
02 Jan - close price
- Market Cap 14,141,000 USD
- Current Price $ 2.95
- High / Low $ 3.02 / 2.81
- Stock P/E N/A
- Book Value 1.43
- EPS -9.73
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.89 %
- ROE -4.05 %
- 52 Week High 13.65
- 52 Week Low 2.80
About
Tempest Therapeutics Inc. (TPST) is a clinical-stage oncology firm based in South San Francisco, California, dedicated to developing innovative small molecules that combine targeted therapies with immune-mediated mechanisms to address various tumors. The company's robust pipeline reflects its commitment to improving patient outcomes in difficult-to-treat oncology indications, positioning Tempest as a leader in cancer research and development. With a focus on advancing cancer therapeutics, Tempest aims to deliver novel treatment options while enhancing stakeholder value and making significant contributions to the fight against cancer.
Analyst Target Price
$9.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-11 | 2025-05-07 | 2025-03-17 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-19 | 2023-11-08 | 2023-08-10 | 2023-05-10 | 2023-03-22 |
| Reported EPS | -0.79 | -2.07 | -3.16 | -0.31 | -0.41 | -0.42 | -0.36 | -0.38 | -0.48 | -0.54 | -0.55 | -0.63 |
| Estimated EPS | -0.2917 | -0.28 | -3.2933 | -0.245 | -0.36 | -0.4 | -0.37 | -0.39 | -0.57 | -0.52 | -0.64 | -0.76 |
| Surprise | -0.4983 | -1.79 | 0.1333 | -0.065 | -0.05 | -0.02 | 0.01 | 0.01 | 0.09 | -0.02 | 0.09 | 0.13 |
| Surprise Percentage | -170.8262% | -639.2857% | 4.0476% | -26.5306% | -13.8889% | -5% | 2.7027% | 2.5641% | 15.7895% | -3.8462% | 14.0625% | 17.1053% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TPST
2025-12-09 05:09:10
Tempest Therapeutics, a clinical-stage biotechnology company, has reported its financial results for the year ended 2024, highlighting significant progress and milestone achievements. The company secured Orphan Drug and Fast Track designations for Amezalpat (TPST-1120) for Hepatocellular Carcinoma (HCC), announced an agreement with Roche for a pivotal trial, and received FDA clearance for a Phase 2 trial of TPST-1495 for Familial Adenomatous Polyposis (FAP). Tempest ended 2024 with $30.3 million in cash and cash equivalents, and a net loss of $41.8 million.
2025-11-26 22:09:10
Tempest Therapeutics' stock experienced a downturn following the announcement of a $4.25 million direct offering. This offering indicates the company is raising capital, which often dilutes existing shareholder value and can lead to a temporary stock price decrease.
2025-11-26 16:05:00
Tempest Therapeutics has closed its previously announced registered direct offering, securing $4.25 million upfront, with potential additional gross proceeds of $4.1 million from short-term unregistered warrants. The company sold 1,172,414 shares of common stock at $3.625 per share and issued warrants to purchase an equal number of shares at an exercise price of $3.50. The net proceeds are intended for working capital and general corporate purposes.
2025-11-26 09:12:01
Tempest Therapeutics, Inc. has successfully completed a registered direct offering and a concurrent private placement, raising approximately $4.25 million in gross proceeds. The offering involved 1,172,414 shares of common stock at $3.625 per share, alongside short-term unregistered warrants. The funds are earmarked for working capital and general corporate purposes, with H.C. Wainwright & Co. acting as the exclusive placement agent.
2025-11-25 08:00:00
Tempest Therapeutics, Inc. announced a definitive agreement for a registered direct offering of common stock and a concurrent private placement of unregistered warrants, totaling up to $8.35 million. The offering includes $4.25 million upfront, with an additional potential $4.1 million from warrant exercises, and is priced at-the-market under Nasdaq rules. The company intends to use the net proceeds for working capital and general corporate purposes.
2025-11-24 05:12:01
Tempest Therapeutics is acquiring four CAR T-cell therapy programs from Erigen LLC and Factor Bioscience in exchange for 8,268,495 shares of common stock, leading to a significant shift in company control where Erigen equityholders will own a majority stake. The deal is contingent on stockholder approval, a $5 million equity financing, and leadership changes including Matt Angel, Ph.D. becoming the new President and CEO. This strategic acquisition aims to expand Tempest's pipeline while continuing development of existing assets.
